People · Operator
Named in public records as an officer, director or promoter · active 2008–2010 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gliamed Inc | — | Biotechnology | Seed | $2.5M | $109.5M | 2008 |
| Renavance Pharma, Inc. | — | Pharmaceuticals | Pre-Seed | $600K | $4.7M | 2009 |
Andrew Busser at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Busser on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Donovan | 1 | 8 |
| David Weinstein | 1 | 3 |
| Barry Dickman | 1 | 2 |
| Mark Kessel | 1 | 1 |
| Andrew Uprichard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.